Nirali Patel1, Shanice A McKenzie1, Christina L Harview2, Allison K Truong1, Vivian Y Shi3, Lucia Chen4, Tristan R Grogan4, Richard G Bennett1,5, Jennifer L Hsiao1. 1. Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 2. Department of Medicine, Harbor-UCLA Medical Center, Graduate Medical Education, Torrance, CA, USA. 3. Division of Dermatology, Department of Medicine, University of Arizona, Tucson, AZ, USA. 4. Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 5. Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Abstract
OBJECTIVE: Isotretinoin has been used off-label in hidradenitis suppurativa (HS) patients with variable results, making it difficult to predict which patients with HS are likely to benefit. MATERIAL AND METHODS: We conducted a retrospective review of HS patients who presented to UCLA HS clinic between August 2009 and March 2018 and collected data on their demographics, reported history of isotretinoin treatment for HS, and treatment response. A number of patient variables were analyzed between the responders and non-responders to see if any were associated with a higher likelihood of a beneficial response. RESULTS: Of the 209 patients, 39 (18.7%) reported prior treatment with isotretinoin. A beneficial response to isotretinoin was reported by 14 (35.9%) patients, while 25 (64.1%) patients reported no response. When comparing responders to non-responders, responders were more likely to have a history of pilonidal cyst (p = .024). Having a concomitant history of regular or cystic acne did not appear to enhance HS treatment response to isotretinoin. CONCLUSIONS: Our data suggest that for HS patients, having a history of pilonidal cyst is associated with a beneficial response to isotretinoin.
OBJECTIVE: Isotretinoin has been used off-label in hidradenitis suppurativa (HS) patients with variable results, making it difficult to predict which patients with HS are likely to benefit. MATERIAL AND METHODS: We conducted a retrospective review of HS patients who presented to UCLA HS clinic between August 2009 and March 2018 and collected data on their demographics, reported history of isotretinoin treatment for HS, and treatment response. A number of patient variables were analyzed between the responders and non-responders to see if any were associated with a higher likelihood of a beneficial response. RESULTS: Of the 209 patients, 39 (18.7%) reported prior treatment with isotretinoin. A beneficial response to isotretinoin was reported by 14 (35.9%) patients, while 25 (64.1%) patients reported no response. When comparing responders to non-responders, responders were more likely to have a history of pilonidal cyst (p = .024). Having a concomitant history of regular or cystic acne did not appear to enhance HS treatment response to isotretinoin. CONCLUSIONS: Our data suggest that for HS patients, having a history of pilonidal cyst is associated with a beneficial response to isotretinoin.
Authors: Terri Shih; Justine R Seivright; Shanice A McKenzie; Christina L Harview; Allison K Truong; Vivian Y Shi; Richard G Bennett; Jennifer L Hsiao Journal: Int J Womens Dermatol Date: 2021-07-17
Authors: Kinnor Das; Steven Daveluy; George Kroumpouzos; Komal Agarwal; Indrashis Podder; Katherine Farnbach; Alex G Ortega-Loayza; Jacek C Szepietowski; Stephan Grabbe; Mohamad Goldust Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241